NMN vs NR
and the molecule your cells run on

Why NAD+ Declines — and Why It Matters

Nicotinamide adenine dinucleotide (NAD+) is not a supplement. It is a cofactor that shows up in hundreds of enzymatic reactions, and in two critical signaling roles: as the essential substrate for sirtuins (the longevity deacetylases) and for PARP enzymes that repair broken DNA strands. Without NAD+, neither process functions at full capacity.

The age-related collapse in NAD+ is well-documented in rodents and increasingly confirmed in human tissue. Blood NAD+ in 60-year-olds runs at roughly 40–60% of levels seen in healthy 20-year-olds. Muscle and liver tissue tell a similar story. The mechanism is not primarily reduced synthesis — it is increased consumption.

CD38: The Culprit Nobody Talks About

In 2016, Camacho-Pereira and colleagues published what may be the most important paper in the NAD+ field for practical supplementation. They identified CD38 — a transmembrane glycohydrolase expressed by immune cells and many other tissues — as the dominant consumer of NAD+ in aged organisms. CD38 expression roughly doubles between young and old animals, and its activity accounts for the majority of NAD+ hydrolysis at any given moment.

The proof of concept was clean: CD38 knockout mice maintain youthful NAD+ levels well into old age, even without supplementation. They also maintain better mitochondrial function, physical performance, and metabolic health. This finding reframes the supplementation question: you are not simply trying to produce more NAD+, you are trying to outpace a drain that accelerates with every passing year.

PARP enzymes add a second layer of competition. During periods of elevated DNA damage — from UV, metabolic stress, or infection — PARP1 activation can rapidly consume local NAD+ pools, triggering a cascade that impairs sirtuin function at exactly the moment the cell most needs repair. The competition between PARP and SIRT for NAD+ represents one of the core tensions in aging biology.

Sirtuins: The Seven Enzymes That Need Your NAD+

The sirtuin family comprises seven proteins — SIRT1 through SIRT7 — each localized to different cellular compartments and each performing distinct deacetylation reactions that require NAD+ as a co-substrate (not merely a cofactor). Every catalytic cycle consumes one NAD+ molecule. This is not incidental: sirtuin activity is directly proportional to NAD+ availability, which means that as NAD+ falls with age, so does the throughput of every process sirtuins regulate.

What Each Sirtuin Does

SIRT1 is the most studied. It operates in the nucleus and cytoplasm, deacetylating histones, p53, NF-κB, and PGC-1α. Its downstream effects include enhanced mitochondrial biogenesis, reduced inflammatory signaling, and improved insulin sensitivity. SIRT1 is the primary target of resveratrol (though that story is complicated) and the main beneficiary of NAD+ restoration.

SIRT3, SIRT4, and SIRT5 are mitochondrial. SIRT3 in particular is a gatekeeper of mitochondrial function — it deacetylates and activates electron transport chain proteins, antioxidant enzymes including MnSOD, and enzymes in the TCA cycle. Loss of SIRT3 activity is directly linked to the mitochondrial dysfunction that characterizes aged cells. Restoring NAD+ reactivates SIRT3 and has been shown to improve mitochondrial membrane potential in aged tissue.

SIRT6 is a nuclear protein focused on genome stability. It promotes DNA repair, regulates telomere maintenance, and suppresses inflammatory gene expression. SIRT6 overexpression extends lifespan in male mice by roughly 15%.

SIRT2 is cytoplasmic and regulates cell cycle progression and metabolic flux. SIRT7 is nucleolar and involved in ribosome biogenesis and stress responses.

The practical implication is that you cannot meaningfully activate sirtuins through caloric restriction, fasting, or exercise without NAD+ as the substrate. These interventions work partly because they increase NAD+ synthesis through the NAMPT pathway — and supplementation with NMN or NR is a direct attempt to accomplish the same thing, at higher concentrations, with less physiological cost.

NR → NMN → NAD+: Understanding the Pathway

Both NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are direct precursors to NAD+ through the salvage pathway. They are not interchangeable; they enter the pathway at different points, with different cellular entry mechanisms, and with different kinetics.

Nicotinamide Riboside (NR)

NR is taken up by cells via specific nucleoside transporters and then phosphorylated by NRK1/NRK2 kinases to produce NMN. That NMN is then adenylated by NMNAT enzymes to yield NAD+. NR has two steps to traverse before becoming NAD+. It was the first of the two precursors to be characterized as a dietary supplement and has the longer clinical track record. Chromadex's Tru Niagen product line has sponsored multiple human safety and pharmacokinetic studies.

NR is structurally simpler than NMN and tends to be more stable at room temperature, which matters for manufacturing and shelf life. Its primary limitation is that the NRK phosphorylation step is rate-limited — cells can only convert NR to NMN as fast as available NRK activity permits.

Nicotinamide Mononucleotide (NMN)

NMN is one step closer to NAD+ than NR. It is converted to NAD+ by NMNAT enzymes, bypassing the NRK bottleneck entirely. The key mechanistic question for NMN was whether it could enter cells directly — since a large nucleotide cannot simply diffuse through lipid bilayers.

This was resolved in 2019 when Imai and colleagues at Washington University identified Slc12a8 as a specific NMN transporter expressed primarily in the small intestine and at lower levels in other tissues. This transporter allows NMN to be taken up intact, entering cells already as NMN rather than having to be imported as NR and reconverted. The discovery had significant implications: it suggested NMN might have faster and more efficient cellular uptake in intestinal tissue.

Sublingual NMN delivery bypasses first-pass intestinal metabolism entirely, with measurable increases in blood NMN within 15–20 minutes of administration in preliminary studies. This route is increasingly favored by practitioners who want peak NAD+ elevation.

Bioavailability: The Real Comparison

Neither molecule survives oral ingestion completely intact. NMN is partially dephosphorylated in the gut lumen to NR before absorption, then reconverted intracellularly. NR is stable through gastric acid and reaches the bloodstream reliably. Both forms are ultimately effective at raising tissue NAD+ in human studies — the question is speed, tissue distribution, and cost efficiency.

NR generally costs less per effective dose and has more published human pharmacokinetic data. NMN, particularly sublingual NMN powder, may achieve faster peak elevation in blood and has been the form used in most Sinclair lab mouse studies. At equivalent gram-doses, the two produce similar NAD+ increases in blood — but tissue-specific differences (particularly in muscle and brain) are still being worked out in ongoing studies.

Human RCTs: What the Evidence Actually Shows

The most critical shift in the NAD+ field happened between 2019 and 2021, when human randomized controlled trials began producing positive outcomes — not just pharmacokinetic confirmation that NAD+ levels rise, but functional metabolic improvements.

Yoshino et al. (2021) — NMN in Postmenopausal Women

This Washington University study is the most cited human NMN trial for functional outcomes. Postmenopausal women with prediabetes received 250mg NMN daily for 10 weeks. The key finding was a significant improvement in skeletal muscle insulin sensitivity — specifically, an increase in muscle glucose uptake as measured by hyperinsulinemic-euglycemic clamp, the gold standard method. The mechanism appeared to involve upregulation of muscle insulin signaling genes (particularly INSR and PIK3CA), consistent with a sirtuin-mediated effect on glucose metabolism. Blood NAD+ metabolites increased significantly in the treatment group.

Liao et al. (2021) — NR RCT

This trial studied NR supplementation in healthy middle-aged adults and found significant increases in blood NAD+ and its metabolites, along with measurable improvements in muscle NAD+ metabolism. Fatigue and blood pressure showed trends toward improvement. The study confirmed that NR is bioavailable and metabolically active in human muscle tissue — the same compartment targeted for aging interventions.

Washington University NMN Safety Studies

A series of dose-escalation and pharmacokinetic studies from Washington University's Klein lab confirmed that single doses of NMN up to 500mg are safe and produce dose-dependent increases in blood NMN and NAD+ metabolites. No adverse effects were observed at any dose. These studies also demonstrated that NMN is effectively converted to NAD+ in human tissue within hours of administration.

Mouse Data: The Sinclair Lab Studies

David Sinclair's lab at Harvard produced a series of landmark papers showing NMN reverses muscle aging in old mice, restores vascular function (critical for tissue oxygenation), and improves endurance capacity. The vascular study showed that aged mice given NMN for two months had muscle capillary density and exercise capacity approaching that of young mice. The mechanism involved SIRT1-dependent upregulation of HIF-1α targets and improved mitochondrial oxygen utilization — NAD+ was the direct driver.

These are mouse studies, and the translation to humans is not guaranteed. But the mechanistic pathway — NAD+ → SIRT1 activation → mitochondrial and vascular function — is conserved between rodents and humans at the molecular level, which makes the human RCTs showing insulin sensitivity improvements particularly meaningful as confirmation.

Dosing, Timing & Stacking: A Practical Framework

The goal with NAD+ precursor supplementation is to achieve a meaningful, sustained elevation in tissue NAD+ — not just a transient blood spike. That requires thinking about dose, timing, and the cofactors that prevent the NAD+ you produce from being immediately degraded by CD38.

Dose Ranges

NMN: The Yoshino 2021 trial used 250mg and found functional outcomes. Most clinical protocols now use 250–500mg daily, with some practitioners going to 1,000mg. Sublingual NMN at 100–250mg may achieve equivalent blood levels to higher oral doses due to bypassing intestinal degradation. There is no established upper dose limit in the human safety data, and doses up to 1,200mg have been administered without adverse effects in open-label studies.

NR: Clinical trials have used 300–1,000mg daily. The 1,000mg dose in multiple trials produced consistent NAD+ elevation with no safety signals. Some practitioners find 300–500mg adequate; others, particularly those using it as a stand-alone intervention without CD38 inhibitors, go to the higher end.

Timing: Food vs. Fasting

Both NMN and NR can be taken with or without food. Some evidence from circadian biology suggests that NAD+ synthesis peaks earlier in the day in sync with the NAMPT rhythm, which has led many practitioners to favor morning dosing. Fasting appears to upregulate NAMPT activity and may enhance the NAD+ response to supplementation, but this effect is modest compared to the absolute dose.

Sublingual NMN should be held under the tongue for 60–90 seconds before swallowing to maximize direct absorption. It can be taken on an empty stomach without GI discomfort, which oral capsules occasionally cause at higher doses.

Apigenin: The CD38 Inhibitor

This is the highest-leverage addition to an NAD+ stack that most people are not taking. Apigenin is a natural flavonoid found in parsley, chamomile, and celery that inhibits CD38 at physiologically achievable concentrations. David Sinclair's own longevity protocol publicly includes apigenin alongside NMN precisely for this reason: by slowing NAD+ degradation, apigenin extends the half-life of the NAD+ you synthesize from NMN or NR.

The mechanism is clean: apigenin is a competitive inhibitor of CD38's NAD+ glycohydrolase activity, with an IC50 in the low-micromolar range achievable with standard supplemental doses of 50–100mg. Quercetin acts similarly but with lower potency. The combination of a NAD+ precursor plus a CD38 inhibitor is, mechanistically, a more complete strategy than either alone.

Resveratrol and SIRT1 Activation

Resveratrol's role is contested — it was initially thought to directly activate SIRT1, but subsequent work showed the in vitro assay was an artifact. What is well-established is that resveratrol activates AMPK, reduces inflammatory signaling, and may amplify the downstream effects of increased NAD+. Whether to include it in a stack is a judgment call; the strongest case for resveratrol is in combination with elevated NAD+ (via NMN/NR), where both arms of sirtuin regulation are addressed simultaneously.

NMN vs NR: The Bottom Line

If you are choosing one, the decision comes down to priorities. NR has the longer safety record in humans, broader pharmacokinetic data, and is generally more affordable per effective dose. It is a reasonable starting point for anyone new to NAD+ supplementation. NR capsules at 300–500mg daily represent the most evidence-backed entry point.

NMN makes more mechanistic sense as the primary precursor if you have access to sublingual delivery, since it bypasses both intestinal metabolism and the NRK rate-limiting step. The Yoshino 2021 data showing functional outcomes at 250mg — a dose lower than most NR trials — suggests NMN may be more potent per milligram in the tissues that matter most for metabolic aging (skeletal muscle).

The most defensible strategy for serious longevity supplementation is not to pick one but to understand what you are actually trying to accomplish: sustained, tissue-level NAD+ elevation with minimal CD38-mediated degradation. That points toward NMN (for speed and muscle uptake) combined with apigenin (to protect what you synthesize) — with NR as a cost-effective way to layer in additional NAD+ precursor supply through the afternoon.

None of this works in isolation. NAD+ is the cofactor that sirtuins and PARPs run on. Providing it in abundance does not guarantee healthy aging — it provides the substrate for the biology you are already doing. Exercise, sleep quality, and caloric regulation all drive NAD+ utilization. Supplementation is most effective when it is not compensating for deficits elsewhere but amplifying a foundation that is already functional.